FrancophonIA/ELRC3.0 huggingface dataset:
English: The following information is intended for healthcare professionals only: Step-by-step instructions for use and handling, reconstitution, and administration
Icelandic: Leiðbeiningar, skref fyrir skref, um notkun og meðhöndlun, blöndun og lyfjagjöf
English: PARTICULARS TO APPEAR ON INTERMEDIATE PACKAGING INTERMEDIATE CARTON - PRE-FILLED SYRINGE MULTIPACK (WITHOUT BLUE BOX)
Icelandic: INNRI UMBÚÐUM INNRI ASKJA FYRIR ÁFYLLTAN LYFJAPENNA Í FJÖLPAKKNINGU (ÁN BLUE BOX)
English: Nucala is provided as a lyophilised, white powder in a single-use vial for subcutaneous injection only.
Icelandic: Nucala er frostþurrkað hvítt duft í einnota hettuglasi, eingöngu til inndælingar undir húð.
English: The safety profile of mepolizumab in severe refractory eosinophilic asthma patients (n=998) treated for a median of 2.8 years (range 4 weeks to 4.5 years) in open-label extension studies was similar to that observed in the placebo-controlled studies.
Icelandic: Öryggi mepolizumabs hjá sjúklingum með alvarlegan þrálátan rauðkyrningaastma (n=998) þar sem miðgildi meðferðartíma var 2,8 ár (á bilinu 4 vikur til 4,5 ár) í opinni framhaldsrannsókn var svipað og kom fram í samanburðarrannsóknum með lyfleysu.
English: The recommended dose for adults and adolescents is 100 mg. You will be given 1 injection every four weeks.
Icelandic: Ráðlagður skammtur fyrir fullorðna og unglinga er 100 mg.
English: Powder for solution for injection 1vial
Icelandic: AÐFERÐ VIÐ LYFJAGJÖF FYRNINGARDAGSETNING
English: Name and address of the manufacturers responsible for batch release
Icelandic: Heiti og heimilisfang framleiðenda sem eru ábyrgir fyrir lokasamþykkt GlaxoSmithKline Manufacturing S.P.A.
English: Lower respiratory tract infection Urinary tract infection Pharyngitis
Icelandic: YTRI UMBÚÐUM ASKJA - ÁFYLLTUR LYFJAPENNI
English: Nucala 100 mg powder for solution for injection mepolizumab
Icelandic: Nucala 100 mg stungulyf, lausn í áfylltri sprautu mepolizumab
English: Pull off the needle cap
Icelandic: Togaðu nálarhettuna af
English: Severe refractory eosinophilic asthma
Icelandic: Heiti og heimilisfang framleiðenda líffræðilegra virkra efna GlaxoSmithKline LLC
English: The baseline mean prednisone equivalent dose was approximately 13 mg per day.
Icelandic: 13 mg á dag af prednisóni.
English: * Systemic reactions including hypersensitivity have been reported at an overall incidence comparable to that of placebo.
Icelandic: * Greint hefur verið frá altækum viðbrögðum, þ.m.t. ofnæmi í heildartíðni sem er sambærileg og fyrir lyfleysu.
English: Each 1 mL pre-filled syringe contains 100 mg of mepolizumab.
Icelandic: Hver 1 ml áfyllt sprauta inniheldur 100 mg af mepolizumabi.
English: Local injection site reactions Pyrexia
Icelandic: INNRI UMBÚÐUM LÍTILLA EININGA
English: White plunge
Icelandic: Hvítur stimpill
English: Exacerbation rate per year
Icelandic: Niðurstöður aðal- og aukaendapunkta í viku
English: The posology of Nucala in children and adolescents aged between 6 to 17 years old with severe refractory eosinophilic asthma has been determined by limited efficacy, pharmacokinetic and pharmacodynamic studies and supported by modelling and simulation data (see sections 5.1 and 5.2).
Icelandic: Skammtar Nucala hjá börnum og unglingum á aldrinum 6 til 17 ára með alvarlegan þrálátan rauðkyrningaastma hafa verið ákvarðaðir samkvæmt takmörkuðum rannsóknum á verkun,
English: Store pen in the original carton in order to protect from light.
Icelandic: Geymið pennann í upprunalegu öskjunni til varnar gegn ljósi.
English: Dispose 9.
Icelandic: Eftir 8 klst.
English: Once reconstituted, Nucala will contain a concentration of 100 mg/mL mepolizumab.
Icelandic: Eftir blöndun inniheldur Nucala mepolizumab í styrknum 100 mg/ml.
English: The trade name (Nucala) and batch number of the administered product should be clearly recorded in the patient file.
Icelandic: Sérheitið (Nucala) og lotunúmerið á lyfinu sem er gefið skal skrá á skýran hátt í skrá sjúklingsins Leiðbeiningar um blöndun fyrir hvert hettuglas
English: • Remove the tray from the carton.
Icelandic: Taktu bakkann úr öskjunni.
English: Gastrointestinal disorders
Icelandic: Skoðunargluggi Nálarvörn
English: In children aged 6 to 11 years old with severe refractory eosinophilic asthma administered mepolizumab subcutaneously every 4 weeks for 52 weeks, blood eosinophils were reduced from a geometric mean count at baseline to week 52 of 306 (n=16) to 48 (n=15) following 40 mg (for a weight < 40kg) and 331 to
Icelandic: Hjá börnum á aldrinum 6 til 11 ára með alvarlegan þrálátan rauðkyrningaastma sem gefið var mepolizumab undir húð á 4 vikna fresti í 52 vikur, fækkaði rauðkyrningum í blóði úr margfeldismeðaltali fjölda í upphafi að viku
English: Needle guard
Icelandic: Harmire Road
English: Administration-related reactions (systemic non allergic)***
Icelandic: Viðbrögð tengd lyfjagjöf (altæk, ekki ofnæmi)
English: Data in cynomolgus monkeys demonstrate that mepolizumab crossed the placenta.
Icelandic: öpum sýna að mepolizumab fer yfir fylgju.
English: Label
Icelandic: Laboratoire
English: Store syringe in the original carton in order to protect from light.
Icelandic: Geymið sprautuna í upprunalegu öskjunni til varnar gegn ljósi.
English: Sodium phosphate dibasic heptahydrate Polysorbate 80
Icelandic: Tvíbasískt natríumfosfatheptahýdrat Pólýsorbat 80
English: Inspection window (medicine
Icelandic: Samantektir um öryggi lyfsins (PSUR)
English: Parasitic infections
Icelandic: LYFJAGERÐARFRÆÐILEGAR UPPLÝSINGAR
English: Nucala 100 mg solution for injection in pre-filled syringe
Icelandic: Nucala 100 mg stungulyf, lausn í áfylltri sprautu
English: • Nucala pre-filled syringe
Icelandic: Tvíbasískt natríumfosfatheptahýdrat
English: • Keep in the carton to protect from light.
Icelandic: Geymið í öskjunni til varnar gegn ljósi.
English: Nucala 100 mg powder for solution for injection
Icelandic: Nucala 100 mg stungulyfsstofn, lausn
English: Hold the pen in place to complete your injection
Icelandic: á sínum stað þangað til inndælingunni er lokið
English: • Do not store it above 30°C.
Icelandic: Geymið við lægri hita en 30°C.
English: 1 mL solution in a Type 1 glass syringe with a fixed needle (stainless steel) in a pre-filled pen.
Icelandic: Nucala 100 mg stungulyf, lausn í áfylltum lyfjapenna 1 ml af lausn í sprautu úr gleri af tegund 1 með áfastri nál (ryðfrítt stál) í áfylltum lyfjapenna.
English: Each 1 ml pre-filled syringe contains 100 mg mepolizumab.
Icelandic: Hver 1 ml áfyllt sprauta inniheldur 100 mg mepolizumab.
English: Reporting of suspected adverse reactions
Icelandic: Rannsókn á fækkun tilvika um versnun
English: Nucala 100 mg solution for injection in pre-filled syringe mepolizumab
Icelandic: Nucala 100 mg stungulyf, lausn í áfylltum lyfjapenna mepolizumab
English: Do not rub your injection site.
Icelandic: Ekki nudda stungustaðinn.
English: Corticosteroids
Icelandic: • nefstífla
English: Of these 34 subjects: 12 received placebo, 9 received mepolizumab 75 mg intravenously, and 13 received 100 mg subcutaneously.
Icelandic: 75 mg af mepolizumabi í bláæð og 13 fengu 100 mg af mepolizumabi undir húð.
English: • Gauze pad or cotton wool ball (not included) Do not perform the injection if you do not have all these.
Icelandic: Grisju eða bómullarhnoðra (fylgir ekki)
English: Clean your injection site
Icelandic: 5. Hreinsaðu stungustaðinn
English: Remove the clear needle cap
Icelandic: 6. Fjarlægðu glæru nálarhettuna
English: PARTICULARS TO APPEAR ON OUTER PACKAGING MULTIPACK CARTON (3 PACKS OF 1 VIAL - WITH BLUE BOX)
Icelandic: SEM EIGA AÐ KOMA FRAM Á YTRI UMBÚÐUM ASKJA FYRIR FJÖLPAKKNINGU (3 PAKKNINGAR
English: For instructions on the reconstitution of the medicinal product before administration, see section 6.6.
Icelandic: Sjá leiðbeiningar í kafla 6.6 um blöndun lyfsins fyrir gjöf.
English: Powder for solution for injection.
Icelandic: Stungulyf, lausn.
English: Table 3: Combined analysis of the rate of clinically significant exacerbations by baseline blood eosinophil count in patients with severe refractory eosinophilic asthma
Icelandic: Sameiginleg greining á tíðni klínískt marktækrar versnunar miðað við fjölda rauðkyrninga í upphafi hjá sjúklingum með alvarlegan þrálátan rauðkyrningaastma
English: Intravenous Mepolizumab
Icelandic: B. FYLGISEÐILL
English: Store in the original carton in order to protect from light.
Icelandic: Geymið í upprunalegu öskjunni til varnar gegn ljósi.
English: Powder for solution for injection 1 vial
Icelandic: AÐFERÐ VIÐ LYFJAGJÖF OG ÍKOMULEIÐ(IR)
English: {text}
Icelandic: {texti}
English: Annex <III> <IV>
Icelandic: Viðauki <III> <IV>
English: Timetable for the implementation of this position
Icelandic: Tímaáætlun fyrir innleiðingu þessarar niðurstöðu
English: Adoption of CMDh position: {Month Year} CMDh meeting
Icelandic: CMDh fundur {mánuður ÁÁÁÁ}
English: <Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through)>
Icelandic: <Breytingar sem gera á í viðeigandi köflum í lyfjaupplýsingunum (nýr texti er undirstrikaður og feitletraður, texti sem á að eyða er gegnumstrikaður)>
English: On the basis of the scientific conclusions for {active substance(s) as EURD list entry} the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing {active substance(s) as EURD list entry} is unchanged subject to the proposed changes to the product information.
Icelandic: Á grundvelli vísindalegra niðurstaðna fyrir {virk(t) efni af EURD listanum} telur CMDh að jafnvægið á milli ávinnings og áhættu af lyfinu/lyfjunum, sem innihalda {virk(t) efni af EURD listanum}, sé óbreytt að því gefnu að áformaðar breytingar á lyfjaupplýsingunum séu gerðar.
English: Taking into account the PRAC Assessment Report on the PSUR(s) for {active substance(s) as EURD list entry}, the scientific conclusions are as follows:
Icelandic: PRAC um PSUR fyrir {virkt efni af EURD listanum} eru vísindalegu niðurstöðurnar svohljóðandi:
English: <Package Leaflet>
Icelandic: <Samantekt á eiginleikum lyfs>
English: <Annex III>
Icelandic: <Viðauki III>
English: The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied.
Icelandic: CMDh kemst að þeirri niðurstöðu að breyta skuli markaðsleyfum lyfja sem tilgreind eru í þessu sameiginlega PSUR mati.
English: To the extent that additional medicinal products containing {active substance(s) as EURD list entry} are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.
Icelandic: CMDh mælir einnig með því að viðkomandi aðildarríki og umsækjandi/markaðsleyfishafar annarra lyfja, sem innihalda {virk(t) efni í EURD lista} og eru með markaðsleyfi innan Evrópusambandsins eða fá markaðsleyfi innan Evrópusambandsins í framtíðinni, taki tillit til þessarar niðurstöðu CMDh.
English: Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder): {DD/MM/YYYY}
Icelandic: Innleiðing aðildarríkjanna á niðurstöðunni (umsókn um breytingu frá markaðsleyfishafa):
English: Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Icelandic: Vísindalegar niðurstöður og ástæður fyrir breytingu
English: Amendments to the product information of the nationally authorised medicinal product(s)
Icelandic: Breytingar á lyfjaupplýsingum lyfja með landsmarkaðsleyfi
English: Transmission to National Competent Authorities of the translations of the annexes to the position: {DD/MM/YYYY}
Icelandic: Þýðingar á viðaukum niðurstöðunnar sendar til yfirvalda í viðkomandi löndum:
English: Annex I
Icelandic: Viðauki II
English: <Conditions to the Marketing Authorisation(s)>
Icelandic: <Forsendur fyrir markaðsleyfunum>
English: Powder and solvent for solution for injection
Icelandic: Lyfjaform Íkomuleið Innri umbúðir
English: Pharmaceutical form
Icelandic: ESB markaðsleyfisnúmer
English: ATCvet code: QJ01BA99.
Icelandic: QJ01BA99.
English: These effects were transitory and usually resolved without any treatment within 5 to 15 days, but could persist up to 49 days.
Icelandic: Áhrifin voru skammvinn og gengu yfirleitt til baka án meðferðar innan 5 til 15 daga, en gátu varað í allt að 49 daga.
English: Bovine 200
Icelandic: Nautgripir 200
English: To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.
Icelandic: Til að tryggja rétta skömmtun skal ákvarða líkamsþyngd eins nákvæmlega og hægt er til að forðast vanskömmtun.
English: In the absence of safety data it is not recommended to use the product in calves less than 4 weeks old.
Icelandic: Vegna skorts á öryggisupplýsingum er ekki mælt með notkun lyfsins hjá kálfum yngri en 4 vikna.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the carton after "EXP".
Icelandic: Ekki skal nota dýralyfið eftir fyrningardagsetningu sem tilgreind er á öskjunni á eftir „EXP“.
English: Ceva Santé Animale 10 av. de La Ballastière 33500 Libourne FRANCE
Icelandic: de La Ballastière 33500 Libourne FRAKKLAND
English: The impact of this difference on anti-inflammatory effects has not been investigated in field trials.
Icelandic: Áhrif þessa mismunar á bólgueyðandi verkunina hafa enn ekki verið rannsökuð í vettvangsrannsóknum.
English: Meloxicam Meloxicam Bovine 20
Icelandic: Meloxíkam Meloxíkam Nautgripir 20
English: 10 av. de La Ballastière
Icelandic: de La Ballastière
English: However, a clear antipyretic effect has been demonstrated in the first 48 hours after administration.
Icelandic: Hins vegar hefur verið sýnt fram á greinilega hitalækkandi verkun á fyrstu 48 klst.
English: The extent of these adverse effects was dose-dependent.
Icelandic: Umfang þessara aukaverkana var skammtaháð.
English: The injection should only be given in the neck area.
Icelandic: Inndælinguna skal aðeins gefa á hálssvæðinu.
English: Surveillance data of the susceptibility of target field isolates from cattle, collected between 2004 and 2012 across Europe, show consistent efficacy of florfenicol with no finding of resistant isolates.
Icelandic: Yfirlitsupplýsingar um næmi stofna úr nautgripum af völdum svæðum sem safnað var á milli 2004 og 2012 um alla Evrópu sýna samræmi í verkun florfeníkóls án þess að ónæmir stofnar fyndust.
English: The product is slightly irritant to the eye. Rinse any splashes from eyes immediately with plenty of water.
Icelandic: Hreinsið allar slettur úr augum strax með miklu vatni.
English: The genes corresponding to these mechanisms are coded on mobile genetic elements such as plasmids, transposon or genes cassettes.
Icelandic: Genin sem svara til þessa verkunarhátta eru táknuð á hreyfanlegum genaþáttum svo sem plasmíðum, stökkul- eða genakassettum (transposon or genes casettes).
English: The single dose volume should not exceed 15 ml per injection site.
Icelandic: Rúmmál staka skammtsins skal ekki fara yfir 15 ml á hverjum stungustað.
English: Meloxicam is extensively bound to plasma proteins (97%) and is distributed in all well-perfused organs.
Icelandic: Próteinbinding meloxíkams í plasma er veruleg (97%) og það dreifist um öll líffæri með gott gegnflæði.
English: Fertility Do not use in adult bulls intended for breeding (see section 4.3).
Icelandic: Dýralyfið má ekki gefa fullorðnum nautum sem notuð eru til undaneldis (sjá kafla 4.3).
English: Otherwise, the use of a multiple-dose syringe is recommended.
Icelandic: Annars er mælt með notkun fjölskammtasprautu.
English: Animal species
Icelandic: Ceva Santé Animale
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals treated in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Icelandic: - Mjög algengar (aukaverkanir koma fyrir hjá fleiri en 1 af hverjum 10 dýrum sem fá meðferð) - Algengar (koma fyrir hjá fleiri en 1 en færri en 10 af hverjum 100 dýrum sem fá meðferð) - Sjaldgæfar (koma fyrir hjá fleiri en 1 en færri en 10 af hverjum 1.000 dýrum sem fá meðferð) - Mjög sjaldgæfar (koma fyrir hjá fleiri en 1 en færri en 10 af hverjum 10.000 dýrum sem fá meðferð)
English: During injection of this product animals may exhibit signs of moderate pain, manifested as movement of the head or neck.
Icelandic: Meðan á inndælingu lyfsins stendur geta komið fram vísbendingar um miðlungsalvarlega verki hjá dýrinu, sem birtast sem hreyfingar á höfði eða hálsi.
English: Meloxicam also has anti-endotoxic properties, because it has been shown to inhibit production of thromboxane B2 induced by E. coli endotoxin after administration in calves, lactating cows and pigs.
Icelandic: Meloxíkam hefur einnig áhrif gegn inneitri, því það hefur reynst hindra framleiðslu tromboxan B2 virkjað af inneitri E. coli eftir gjöf hjá kálfum, mjólkandi kúm og svínum.
English: Muscle Liver Kidney Milk
Icelandic: Vöðvi Lifur Nýru Mjólk
English: Resistance to florfenicol is mainly mediated by an efflux system due to a specific (Flo-R) or multidrug transporter (AcrAB-TolC).
Icelandic: Ónæmi fyrir florfeníkóli er aðallega miðlað af útflæðiskerfi af völdum sértækrar (Flo-R) eða fjöllyfjaferju (AcrAB-TolC).
English: The active substances in Zeleris are allowed substances as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Icelandic: Virku efnin í Zeleris eru leyfð innihaldsefni samkvæmt lýsingu í töflu 1 í viðaukanum við reglugerð framkvæmdastjórnarinnar (ESB) nr. 37/2010:
English: Injection site reactions (mostly swelling, induration, heat and pain) were very commonly observed after subcutaneous administration of the product.
Icelandic: Viðbrögð á stungustað (aðallega þroti, herslismyndun, hiti og verkur) voru mjög algeng eftir gjöf lyfsins undir húð.
English: Florfenicol
Icelandic: Florfeníkól
English: Muscle Liver Kidney
Icelandic: Vöðvi Lifur Nýru
English: People with known hypersensitivity to florfenicol, meloxicam or to any of the excipients should avoid contact with the veterinary medicinal product.
Icelandic: Þeir sem hafa ofnæmi fyrir florfeníkóli, meloxíkami eða einhverju hjálparefnanna skulu forðast snertingu við dýralyfið.
English: Repeated weekly administration of a 5x dose was fatal in 7 out of 8 calves after the third administration.
Icelandic: Endurtekin vikuleg gjöf á 5x skammti var banvæn hjá 7 af 8 kálfum eftir þriðju gjöf.
English: MRLs (µg/kg)
Icelandic: Bil (µg/ml)
English: Do not use in adult bulls intended for breeding.
Icelandic: Gefið ekki fullorðnum nautum ætluðum til undaneldis.
English: The bioavailability of meloxicam in this combination product is lower compared to the use of meloxicam when administered on its own.
Icelandic: Aðgengi meloxíkams í þessu samsetta lyfi er minna en við gjöf meloxíkams eins sér.
English: EXP Once broached, use within 28 days.
Icelandic: EXP Rofna pakkningu skal nota innan 28 daga.
English: The in vitro Minimum Inhibitory Concentration (MIC) distribution values for these field isolates are presented in the table below.
Icelandic: Dreifing in vitro gilda fyrir lágmarksheftistyrk (MIC) fyrir stofna frá þessum svæðum er sýnd í töflunni hér fyrir neðan.
English: Fertility Do not use in adult bulls intended for breeding (see section “Contraindications”).
Icelandic: Dýralyfið má ekki gefa fullorðnum nautum sem notuð eru til undaneldis (sjá kaflann „Frábendingar“).
English: Sum of florfenicol and its metabolites measured as florfenicolamine
Icelandic: Summa florfeníkóls og umbrotsefna þess, mæld sem florfeníkólamín
English: Repeated weekly administration of a 3x dose was fatal in 1 out of 8 calves after the third administration.
Icelandic: Endurtekin vikuleg gjöf á 3x skammti var banvæn hjá 1 af 8 kálfum eftir þriðju gjöf.
English: EXP Once broached, use within 28 days, by __/__/__.
Icelandic: EXP Rofna pakkningu skal nota innan 28 daga, fyrir _/_/_
English: Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or when there is evidence of ulcerogenic gastrointestinal lesions.
Icelandic: Gefið ekki dýrum sem eru með skerta lifrar-, hjarta- eða nýrnastarfsemi og blæðingasjúkdóma eða ef vísbendingar eru um sár í meltingarvegi.
English: Translucent multi-layered plastic vials (polypropylene/ethylene vinyl alcohol/polypropylene) with chlorobutyl rubber stoppers and aluminium and plastic flip capsules, containing 50 ml, 100 ml or 250 ml.
Icelandic: Hálfgegnsæ fjöllaga plasthettuglös (pólýprópýlen/etýlenvínýlalkóhól/pólýprópýlen) með klóróbútýl gúmmítöppum og ál- og plasthettum, sem innihalda 50 ml, 100 ml eða 250 ml.
English: In pre-ruminant calves, repeated administration of the recommended dose once per week for three weeks was well tolerated, as well as a single administration of 3 times (3x) the recommended dose.
Icelandic: Hjá kálfum á mjólkurtímabili (pre-ruminant) þoldist endurtekin gjöf ráðlagðs skammts einu sinni í viku í þrjár vikur vel, svo og stök gjöf á 3 földum (3x) ráðlögðum skammti.
English: Repeated weekly administration of overdoses (3x and 5x the recommended dose) in calves was associated with decreased milk consumption, decreased weight gain, loose faeces or diarrhoea.
Icelandic: Endurtekin vikuleg gjöf of stórra skammta (3x og 5x ráðlagðra skammta) hjá kálfum tengdist minni mjólkurneyslu, skertri þyngdaraukningu, linum hægðum eða niðurgangi.
English: Florfenicol is considered to be a bacteriostatic agent, but in vitro studies demonstrate its bactericidal activity against Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Icelandic: Florfeníkól er talið vera bakteríuheftandi lyf, en in vitro rannsóknir staðfesta bakteríudrepandi áhrif þess á Mannheimia haemolytica, Pasteurella multocida og Histophilus somni.
English: Florfenicol is largely distributed in whole body and has a low plasma protein binding (approximately 20%).
Icelandic: Florfeníkól dreifist verulega um allan líkamann og próteinbinding er lítil (u.þ.b. 20%).
English: Florfenicol is a synthetic broad-spectrum antibiotic effective against most Gram-positive and Gramnegative bacteria isolated from domestic animals.
Icelandic: Florfeníkól er samtengt breiðvirkt sýklalyf, virkt gegn flestum Gram-jákvæðum og Gram-neikvæðum bakteríum sem einangraðar eru úr húsdýrum.
English: Laboratory tests have shown that florfenicol is active against the most commonly isolated bacterial pathogens involved in bovine respiratory disease which include Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Icelandic: Rannsóknir hafa sýnt að florfeníkól er virkt gegn flestum algengum einangruðum bakteríum sem valda öndunarfærasýkingum í nautgripum sem eru m.a. Mannheimia haemolytica, Pasteurella multocida og Histophilus somni.
English: Cardboard box with 1 vial of 50 ml, 100 ml or 250 ml.
Icelandic: Pappaaskja með 1 hettuglasi með 50 ml, 100 ml eða 250 ml.
English: Cattle.
Icelandic: Nautgripir.
English: Dimethyl sulfoxide Glycerol formal, stabilised
Icelandic: Tvímetýlsúlfoxíð Glýseról formal, gert stöðugt
English: 400 mg Meloxicam 5 mg.
Icelandic: 400 mg Meloxíkam 5 mg
English: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects.
Icelandic: Meloxam er bólgueyðandi gigtarlyf sem ekki er steri í flokki oxíkama, sem virkar með því að hindra nýmyndun prostaglandína og hefur þannig bólgueyðandi, bjúghemjandi, verkjastillandi og hitalækkandi áhrif.
English: Florfenicol acts by inhibiting protein synthesis at the ribosomal level and its action is bacteriostatic and time-dependent.
Icelandic: Florfeníkól virkar með því að hindra nýmyndun próteina í ríbósómum og virknin er bakteríuheftandi og tímaháð.